Biotech | May 16, 2022
Antengene announces commercial availability of Xpovio in China
The drug will be available in 600 hospitals and 105 DTPs
The drug will be available in 600 hospitals and 105 DTPs
Capabilities include the latest in sterile lyophilization and liquid filling technology to support global pharmaceutical supply chain, keeping pace with industry trends
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
Image and data analysis of rich spatial information from mIF images can accelerate tissue biomarker discovery and validation
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
The company enters into collaborations with leading next-generation sequencing (NGS) companies to facilitate trial enrollment for PRECISION 1, the Company’s Phase 2 registrational trial
RNAstorm and DNAstorm RNA/DNA extraction kits will be sold exclusively through the Biotium website and authorized distributors
Subscribe To Our Newsletter & Stay Updated
